Matches in SemOpenAlex for { <https://semopenalex.org/work/W2036222335> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- W2036222335 endingPage "211" @default.
- W2036222335 startingPage "208" @default.
- W2036222335 abstract "Ibandronate is an aminobisphosphonate that specifically binds to bone mineral and inhibits the activity of osteoclasts. It is one of the most potent bisphosphonates that are currently being tested in clinical trials in patients with metabolic bone disorders and with osteoporosis. In animal models, ibandronate is twice, 10 times, 50 times, and 500 times more powerful than risedronate, alendronate, pamidronate, and clodronate, respectively. We retrospectively analyzed the clinical results of three studies with ibandronate in 340 patients and of two studies with pamidronate in 80 patients, leading to the registration of both agents for the treatment of malignant hypercalcemia. Ibandronate can be used in patients with malignant hypercalcemia with and without metastases. A single infusion of 2 to 6 mg ibandronate effectively reduces elevated serum calcium levels. The success of treatment depends on the baseline calcium level and the dose used. The time to normalization of the serum calcium concentration varies between 2 and 7 days, with 4 days being usual in most patients. The median time to relapse (i. e., a re-increase in serum calcium) is 26 days and is similar for all doses. Treatment is more successful in patients with local osteolytic tumors (breast and hematologic tumors, response rates up to 100%) than in those with predominantly humorally induced hypercalcemia in the other solid tumor types. Adverse reactions are minor, generally of no clinical relevance, and rarely require treatment. Local tolerability is excellent. Efficacy of ibandronate (Bondronat<sup>®</sup> ) is well comparable to that of other bisphosphonates, especially to those with an amino group like pamidronate. Ibandronate provides an effective and well-tolerated treatment for tumor-induced hypercalcemia." @default.
- W2036222335 created "2016-06-24" @default.
- W2036222335 creator A5000870045 @default.
- W2036222335 creator A5006902955 @default.
- W2036222335 date "1999-01-01" @default.
- W2036222335 modified "2023-09-26" @default.
- W2036222335 title "The New Bisphosphonate Ibandronate in the Treatment of Tumor-Induced Hypercalcemia" @default.
- W2036222335 cites W1883130365 @default.
- W2036222335 cites W1966434911 @default.
- W2036222335 cites W2012023442 @default.
- W2036222335 cites W2051616961 @default.
- W2036222335 cites W2146306121 @default.
- W2036222335 doi "https://doi.org/10.1159/000026952" @default.
- W2036222335 hasPublicationYear "1999" @default.
- W2036222335 type Work @default.
- W2036222335 sameAs 2036222335 @default.
- W2036222335 citedByCount "4" @default.
- W2036222335 crossrefType "journal-article" @default.
- W2036222335 hasAuthorship W2036222335A5000870045 @default.
- W2036222335 hasAuthorship W2036222335A5006902955 @default.
- W2036222335 hasConcept C126322002 @default.
- W2036222335 hasConcept C143998085 @default.
- W2036222335 hasConcept C2776541429 @default.
- W2036222335 hasConcept C2777251235 @default.
- W2036222335 hasConcept C502942594 @default.
- W2036222335 hasConcept C71924100 @default.
- W2036222335 hasConceptScore W2036222335C126322002 @default.
- W2036222335 hasConceptScore W2036222335C143998085 @default.
- W2036222335 hasConceptScore W2036222335C2776541429 @default.
- W2036222335 hasConceptScore W2036222335C2777251235 @default.
- W2036222335 hasConceptScore W2036222335C502942594 @default.
- W2036222335 hasConceptScore W2036222335C71924100 @default.
- W2036222335 hasIssue "3" @default.
- W2036222335 hasLocation W20362223351 @default.
- W2036222335 hasOpenAccess W2036222335 @default.
- W2036222335 hasPrimaryLocation W20362223351 @default.
- W2036222335 hasRelatedWork W1967513861 @default.
- W2036222335 hasRelatedWork W2009345456 @default.
- W2036222335 hasRelatedWork W2009841704 @default.
- W2036222335 hasRelatedWork W2013276326 @default.
- W2036222335 hasRelatedWork W2050550813 @default.
- W2036222335 hasRelatedWork W2079738332 @default.
- W2036222335 hasRelatedWork W2083456321 @default.
- W2036222335 hasRelatedWork W2119701147 @default.
- W2036222335 hasRelatedWork W2315404004 @default.
- W2036222335 hasRelatedWork W2412860635 @default.
- W2036222335 hasVolume "22" @default.
- W2036222335 isParatext "false" @default.
- W2036222335 isRetracted "false" @default.
- W2036222335 magId "2036222335" @default.
- W2036222335 workType "article" @default.